EE200300416A - Ravimvorm - Google Patents

Ravimvorm

Info

Publication number: EE200300416A
Authority: EE; Estonia
Prior art keywords: pharmaceutical form; pharmaceutical
Prior art date: 2001-02-27

Application number

EEP200300416A

Other languages

English (en)

Inventor

Frances Bateman Nicola

Kay Cahill Julie

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-27

Filing date

2002-02-22

Publication date

2003-12-15

2001-02-27 Priority claimed from GB0104749A external-priority patent/GB2372444A/en

2001-07-19 Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx

2002-02-22 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2003-12-15 Publication of EE200300416A publication Critical patent/EE200300416A/et

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Physiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Oncology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

EEP200300416A 2001-02-27 2002-02-22 Ravimvorm EE200300416A (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0104749A GB2372444A (en)	2001-02-27	2001-02-27	A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv)	2001-07-19	2001-07-19	Pharmaceutical formulation
PCT/GB2002/000766 WO2002067893A2 (en)	2001-02-27	2002-02-22	Pharmaceutical formulation comprising bicalutamide

Publications (1)

Publication Number	Publication Date
EE200300416A true EE200300416A (et)	2003-12-15

Family

ID=26245766

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200300416A EE200300416A (et)	2001-02-27	2002-02-22	Ravimvorm

Country Status (22)

Country	Link
US (1)	US20040067257A1 (et)
EP (1)	EP1368001B1 (et)
JP (2)	JP3548566B2 (et)
KR (1)	KR20030077042A (et)
CN (1)	CN1503662A (et)
AR (1)	AR032912A1 (et)
AT (1)	ATE307571T1 (et)
CA (1)	CA2439366A1 (et)
CZ (1)	CZ20032225A3 (et)
DE (1)	DE60206889T2 (et)
EE (1)	EE200300416A (et)
HU (1)	HUP0302847A3 (et)
IL (1)	IL157389A0 (et)
IS (1)	IS6915A (et)
MX (1)	MXPA03007641A (et)
NO (1)	NO20033785L (et)
NZ (1)	NZ527532A (et)
PL (1)	PL365746A1 (et)
RU (1)	RU2003128971A (et)
SK (1)	SK10722003A3 (et)
UY (1)	UY27186A1 (et)
WO (1)	WO2002067893A2 (et)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103838D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product
TWI355276B (en) *	2003-01-14	2012-01-01	Akira Tsuji	Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) *	2003-05-14	2005-01-13	Arturo Siles Ortega	Bicalutamide compositions
WO2005074991A1 (ja) *	2004-02-09	2005-08-18	Kabushiki Kaisha Sangi	抗腫瘍剤
KR100539706B1 (ko) *	2005-01-25	2005-12-28	지엘팜텍 주식회사	타크로리무스 및 장용성 고분자를 함유하는 고체분산체
CN101128195A (zh) *	2005-02-23	2008-02-20	阿斯利康(瑞典)有限公司	用于递送增加的稳态血浆水平的比卡鲁胺
JP5097540B2 (ja) *	2005-04-06	2012-12-12	株式会社サンギ	腸管吸収用抗腫瘍剤
US7785629B2 (en) *	2005-06-21	2010-08-31	Helm Ag	Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) *	2006-06-16	2012-10-17	トーアエイヨー株式会社	腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) *	2006-08-17	2008-02-21	Gawande Rahul S	Bicalutamide compositions
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
BRPI0814423B1 (pt)	2007-07-17	2022-04-19	Plexxikon, Inc	Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos
WO2009038112A1 (ja)	2007-09-21	2009-03-26	Shionogi & Co., Ltd.	Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP5204452B2 (ja) *	2007-10-02	2013-06-05	日医工株式会社	ビカルタミド含有製剤
EP2219624A2 (en) *	2007-11-08	2010-08-25	Glaxo Group Limited	Pharmaceutical formulations
MY160737A (en)	2009-04-03	2017-03-15	Hoffmann La Roche	Propane-i-sulfonic acid {3- [5-(4-chloro-phenyl) -1h -pyrrolo [2, 3-b] pyridine-3-carbonyl] -2,4 difluoro-phenyl} - amide compositions and uses thereof
CN101987086B (zh) *	2009-08-03	2012-07-18	北京化工大学	一种超细比卡鲁胺口服片剂及其制备方法
US8329724B2 (en)	2009-08-03	2012-12-11	Hoffmann-La Roche Inc.	Process for the manufacture of pharmaceutically active compounds
SG10201407129SA (en)	2009-11-06	2014-12-30	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
US9259389B2 (en)	2009-12-18	2016-02-16	Endotis Pharma	Pharmaceutical oral dosage form containing a synthetic oligosaccharide
CN102525876B (zh) *	2010-12-15	2014-03-12	西安力邦医药科技有限责任公司	阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) *	2010-12-20	2013-11-20	西安力邦医药科技有限责任公司	拉米夫定固体分散体、其制备方法、药物组合物和用途
CN103517710B (zh)	2011-02-07	2017-05-31	普莱希科公司	用于激酶调节的化合物
TWI558702B (zh)	2011-02-21	2016-11-21	普雷辛肯公司	醫藥活性物質的固態形式
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
RS62676B1 (sr)	2012-09-11	2021-12-31	Medivation Prostate Therapeutics Llc	Formulacije enzalutamida
AU2015300798A1 (en) *	2014-08-07	2017-02-02	Pharmacyclics Llc	Novel formulations of a Bruton's tyrosine kinase inhibitor
JP6830892B2 (ja)	2014-12-05	2021-02-17	アラゴンファーマシューティカルズ，インコーポレイテッド	抗癌性組成物
CN114886852A (zh)	2014-12-05	2022-08-12	阿拉贡药品公司	抗癌组合物
AU2017376544C1 (en) *	2016-12-15	2021-06-24	Hua Medicine (Shanghai) Ltd.	Oral preparation of glucokinase activator and preparation method therefor
KR20210151185A (ko)	2019-04-11	2021-12-13	알.피.쉐러 테크놀러지즈 엘엘씨	난투과성 단백질, 펩타이드 및 소분자의 경구 전달을 위한 제형
GB2584341B (en) *	2019-05-31	2023-03-01	Gw Res Ltd	Cannabinoid formulations
US11344526B2 (en)	2020-03-20	2022-05-31	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) *	2020-03-20	2021-11-16	The Regents Of The University Of California	Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0100172B1 (en) *	1982-07-23	1987-08-12	Imperial Chemical Industries Plc	Amide derivatives
ES2111065T5 (es) *	1991-04-16	2005-06-16	Nippon Shinyaku Company, Limited	Procedimiento para producir una dispersion solida.
WO1995019770A1 (en) *	1994-01-21	1995-07-27	Sepracor, Inc.	Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US20030059471A1 (en) *	1997-12-15	2003-03-27	Compton Bruce Jon	Oral delivery formulation
DE60211139T2 (de) *	2001-04-02	2007-03-01	Astrazeneca Ab	Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
SE0103424D0 (sv) *	2001-10-15	2001-10-15	Astrazeneca Ab	Pharmaceutical formulation
SE0103839D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product

2002
- 2002-02-22 HU HU0302847A patent/HUP0302847A3/hu unknown
- 2002-02-22 EP EP02712105A patent/EP1368001B1/en not_active Expired - Lifetime
- 2002-02-22 KR KR10-2003-7011178A patent/KR20030077042A/ko not_active Withdrawn
- 2002-02-22 CZ CZ20032225A patent/CZ20032225A3/cs unknown
- 2002-02-22 CA CA002439366A patent/CA2439366A1/en not_active Abandoned
- 2002-02-22 JP JP2002567261A patent/JP3548566B2/ja not_active Expired - Fee Related
- 2002-02-22 MX MXPA03007641A patent/MXPA03007641A/es unknown
- 2002-02-22 RU RU2003128971/15A patent/RU2003128971A/ru not_active Application Discontinuation
- 2002-02-22 SK SK1072-2003A patent/SK10722003A3/sk unknown
- 2002-02-22 IL IL15738902A patent/IL157389A0/xx unknown
- 2002-02-22 EE EEP200300416A patent/EE200300416A/et unknown
- 2002-02-22 PL PL02365746A patent/PL365746A1/xx not_active Application Discontinuation
- 2002-02-22 AT AT02712105T patent/ATE307571T1/de not_active IP Right Cessation
- 2002-02-22 WO PCT/GB2002/000766 patent/WO2002067893A2/en not_active Ceased
- 2002-02-22 NZ NZ527532A patent/NZ527532A/xx unknown
- 2002-02-22 DE DE60206889T patent/DE60206889T2/de not_active Expired - Fee Related
- 2002-02-22 CN CNA028087356A patent/CN1503662A/zh active Pending
- 2002-02-22 US US10/468,276 patent/US20040067257A1/en not_active Abandoned
- 2002-02-26 UY UY27186A patent/UY27186A1/es not_active Application Discontinuation
- 2002-02-27 AR ARP020100712A patent/AR032912A1/es not_active Application Discontinuation
2003
- 2003-08-15 IS IS6915A patent/IS6915A/is unknown
- 2003-08-26 NO NO20033785A patent/NO20033785L/no not_active Application Discontinuation
2004
- 2004-02-18 JP JP2004041583A patent/JP2004143185A/ja active Pending

Also Published As

Publication number	Publication date
HUP0302847A2 (hu)	2003-12-29
CZ20032225A3 (cs)	2003-11-12
DE60206889D1 (de)	2005-12-01
NZ527532A (en)	2004-12-24
WO2002067893A3 (en)	2003-01-16
EP1368001B1 (en)	2005-10-26
WO2002067893A2 (en)	2002-09-06
IS6915A (is)	2003-08-15
IL157389A0 (en)	2004-05-12
NO20033785D0 (no)	2003-08-26
MXPA03007641A (es)	2003-12-04
CN1503662A (zh)	2004-06-09
EP1368001A2 (en)	2003-12-10
JP2004521918A (ja)	2004-07-22
KR20030077042A (ko)	2003-09-29
DE60206889T2 (de)	2006-07-27
SK10722003A3 (sk)	2004-02-03
CA2439366A1 (en)	2002-09-06
ATE307571T1 (de)	2005-11-15
RU2003128971A (ru)	2005-03-10
US20040067257A1 (en)	2004-04-08
UY27186A1 (es)	2002-09-30
HUP0302847A3 (en)	2005-05-30
JP3548566B2 (ja)	2004-07-28
JP2004143185A (ja)	2004-05-20
PL365746A1 (en)	2005-01-10
NO20033785L (no)	2003-10-24
AR032912A1 (es)	2003-12-03

Publication	Publication Date	Title
EE200300416A (et)	2003-12-15	Ravimvorm
FI20011478L (fi)	2003-01-06	Farmaseuttinen koostumus
NO20033556L (no)	2003-10-09	Farmasöytiske formuleringer
NO20033384D0 (no)	2003-07-29	Farmasöytisk formulering
PL367180A1 (pl)	2005-02-21	Trwała kompozycja farmaceutyczna
DE60204063D1 (de)	2005-06-16	Blisterverpackung
NO20035315D0 (no)	2003-11-28	Farmasöytiske kombinasjoner
NO20035627D0 (no)	2003-12-15	Farmasöytisk formulering
FI20022128A0 (fi)	2002-12-03	Farmaseuttinen koostumus
DE50209245D1 (de)	2007-02-22	Neuroprotektives medikament
ATA18372001A (de)	2005-07-15	Gelenksbolzenbaueinheit
ATA13992002A (de)	2003-10-15	Schlackengranulierungsanlage
FI20012242A0 (fi)	2001-11-19	Uudet farmaseuttiset yhdisteet
EE200300378A (et)	2003-10-15	Farmatseutiline kompositsioon
EP1413314A4 (en)	2004-12-22	MEDICAL COMPOSITIONS
AT500276B8 (de)	2007-02-15	Radschwenksystem
ATA7462001A (de)	2002-01-15	Radspannwerk
SE0103116D0 (sv)	2001-09-17	Pharmaceutical combination
NO20041236L (no)	2004-03-24	Farmasoytisk formulering
FI5468U1 (fi)	2002-07-30	Farmaseuttinen koostumus
SE0102823D0 (sv)	2001-08-24	New drug
ATA6162001A (de)	2002-11-15	Schneekette
SE0102069D0 (sv)	2001-06-21	Pharmaceutical formulation
SE0101326D0 (sv)	2001-04-12	Pharmaceutical formulation
SE0101171D0 (sv)	2001-04-02	Pharmaceutical formulation